Archive | Corporate RSS feed for this section

Why Would a Broker Feel Entitled Not to Repay $1.8 Million in Loans to Ex-Employer Merrill Lynch?

28 Oct

In Lahoud v. Merrill Lynch, Pierce, Fenner & Smith, Inc., United States District Judge Margaret M. Garnett denied petitioner John Lahoud’s motion to vacate a FINRA arbitration award and granted Merrill Lynch’s cross-motion to confirm it. The court upheld the arbitration panel’s order requiring Lahoud to repay $1,181,594.35 in outstanding principal balances on corporate promissory notes, plus daily interest, costs, and $150,000 in attorney’s fees.

John Lahoud had written three loans to himself from Merrill Lynch’s accounts between 2013-7 when he worked there as a broker and advisor. Instead of repaying these loans, as his contract dictated, after leaving the firm in 2021 to begin working for a competitor, he decided to keep the money. He was unpersuaded by a demand letter, forcing Merrill to commence this FINRA arbitration. To defend his right to keep these funds, Lahoud filed counterclaims on December 12, 2022 with the defense of a constructive discharge. He accused Merrill of breach of contract, interference with his pursuit of economic advantage and unfair competition and unjust enrichment, specifically for permitting other advisors to solicit his clients, and of mercilessly alleging he was guilty of mortgage fraud to force him to resign. FINRA ruled for Merrill.

While this case seems to be a simple corporate dispute, the Epstein Files include several unrepaid loans that have been made by brokers who were involved in financial misconduct, including Jeffrey Epstein himself at Bear Stearns. At Epstein’s companies, his attorney Indyke was also given over $7 million in loans as “retention bonuses” that were expected to be forgiven. Similar though lower-valued retention “loans” were given to around ten other employees. ICIC made $290 million in loans “of which all but perhaps $25 million is apparently lost. About $93.5 million… were used to purchase shares of BCCI itself”. While Merrill Lynch is not directly implicated, Epstein met with a Dr. Merrill in 2016, which might have been code for Merrill Lynch. The fact that Lahoud is insisting on keeping loans he is contractually obligated to return suggests he was promised he could keep these funds in exchange for something nefarious, as in the Epstein Files such non-repayments tend to be for items that cannot be legally credited and made to people who are attempting to dodge taxes.

Back in Lahoud’s case, the court found that Lahoud was not forced to depart, but rather resigned after negotiating a high-paying new position, not only for himself but also for his whole team. Lahoud was also contesting the $150,000 for two years in attorney’s fees as excessive, despite his own salary being in the millions. Since mega corporations defending their millions tend to be charged top-rates by their lawyers, it is certainly logical that forcing Merrill to take him to court generated a high legal fee. It would be illogical to levy such charges due to a loan non-repayment onto the loan-issuer.

And why would anybody making hundreds of thousands need a non-nefarious loan for such enormous sums? The final $1.8 million due was only a portion of the millions Lahoud had repaid before departing. Just one of his promissory notes was for $4.2 million. This case raises a lot of questions and suggests a need for a forensic investigation into the accounts of both Lahoud and his team and Merrill Lynch during the years Lahoud took out these loans. The bits of information available in the public filing are insufficient to reach conclusions, but they suggest many malevolent theories.

Suggested Citation:
Faktorovich, Anna. “Why Would a Broker Feel Entitled Not to Repay $1.8 Million in Loans to Ex-Employer Merrill Lynch?” Anaphora’s Law Review (October 28, 2026).

Remunerating Doctors to Buy Blood Clot Treating Devices: Illegal?

27 Oct

On September 22, 2026, U.S. District Judge Gregory H. Woods dismissed a class-action securities fraud case: Michiana Area Electrical Workers’ Pension Fund v. Inari Medical Inc., et al. (2026). The investors had failed to prove with sufficient specificity that the company had engaged in an illegal doctor-kickback scheme or deliberately misled shareholders to inflate its stock price.

The evidence confirmed that Inari was providing up to $50,000 in corporate dinners, junkets a vacation destinations and NASCAR race tickets in exchange for doctors ordering Inari’s products. But such spending was found to be standard in this industry (according to the AdvaMed Code of Ethics on Interactions with Healthcare Professionals), as opposed to amounting to illegal kickbacks. The filers attempted to argue AdvaMed does specify a “per individual limit of $3,000 for gifts and promotional materials.” While one salesperson spent $50,000 on physician dinners over a three-month period, and another $5,000, each physician was not receiving over $3,000.

Inari is a manufacturer of technologies that treat and remove blood clots. The case was filed against Inari’s three former administrators: CEO, COO and CFO. They had operated a successful doctor-buttering scheme between 2021-4, before, on February 28, 2024, revealing to investors that they had received a civil investigative demand from the Department of Justice (DOJ), which was investigating if Inari’s practices were violating the Anti-Kickback Statute and the False Claims Act. This revelation led to a single-day 21% drop in Inari’s stock price, at a loss of $700 million in market capitalization.

Since this meant three invested pension funds had lost a lot of money, in May to June 2024, they filed a joint complaint over securities fraud and racketeering. One of the pension funds’ objections was that the administrators had collected $155.5 million in profits during the three years when the DOJ probe was active, but was not publicly disclosed by Inari.

The pension funds lost partly because DOJ’s probe failed to uncover evidence the gifts to physicians were illegal, and this meant the civil lawsuit lacked evidence underlying crimes had occurred. The administrators were allowed to delay disclosure until the date when they revealed it: they did not break the law by their delay. And they were acting in the best interests of shareholders by not disclosing earlier, since the stock would have plummeted earlier, and too soon before the DOJ had to report they had not found any prosecutable law-breaking. The filers might have assumed DOJ records would have what apparently failed to surface in discovery: they had no specific names of a doctor, date, or venue where a provably illegal transaction had taken place. All records proved was that Inari had spent a lot of money on sales and marketing.

The funds might have attached erroneous assumptions by the finding in the Purdue Pharma fraud case. It seems on the surface that Inari spending 68% of its revenue on sales and administration to cultivate customers was as illegal as what Purdue was doing. But in Purdue, the feds were able to prove systemic quid pro quo financial bribery in paying fraudulent “speaker fees” and consulting retainers well over the $3,000 limit to serve as pushers of prescriptions that they were fraudulently selling as safe when they were deadly addictive. There was nothing proven to be fraudulent with Inari’s core devices. Most small businesses wish it was illegal for giant corporations to spend such enormous sums on convincing people to buy their products. But his is how capitalism works: not the best products but the most effective sales campaigns win market share. The legality of Inari’s actions should have been apparent through brisk disclosures without a years-long DOJ audit. If DOJ had dropped their case upon failing to find wrongdoing, investors would not have lost millions in a panic sell-off. The public is too trusting in government actions: when the government declares it is auditing somebody, the public assumes the entity is guilty before the test results come in.

Suggested Citation:
Faktorovich, Anna. “Remunerating Doctors to Buy Blood Clot Treating Devices: Illegal?” Anaphora’s Law Review (October 27, 2026).